UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000031950
Receipt No. R000035259
Scientific Title Relationship between treatment response of initial DMARD and outcome of treat-to-target strategy in patients with early rheumatoid arthritis: Nationwide Inception Cohort of Early Rheumatoid arthritis patients in Japan
Date of disclosure of the study information 2018/04/01
Last modified on 2019/02/20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Relationship between treatment response of initial DMARD and outcome of treat-to-target strategy in patients with early rheumatoid arthritis: Nationwide Inception Cohort of Early Rheumatoid arthritis patients in Japan
Acronym NICER-J
Scientific Title Relationship between treatment response of initial DMARD and outcome of treat-to-target strategy in patients with early rheumatoid arthritis: Nationwide Inception Cohort of Early Rheumatoid arthritis patients in Japan
Scientific Title:Acronym NICER-J
Region
Japan

Condition
Condition Rheumatoid Arthritis
Classification by specialty
Clinical immunology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To set inception cohort of newly diagnosed rheumatoid arthritis patient with no treatment or nearly untreatment and to explore the relationship between the treatment response of csDMARD including MTX and the effect of adapting therapy using bDMARD, tsDMARD or csDMARD .
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes 1. To explore relationship between the changes in disease activity by csDMARD treatment and that of disease activity up to 24 weeks for the first adapting therapy (bDMARD / tsDMARD, or csDMARD). Also analyze by each adapting therapy.
2. To identify factors related to achieving remission at week 24. Also analyze by each adapting therapy.
Key secondary outcomes 1) To explore the relationship between the changes in disease activity by initial treatment after registration and the transition of disease activity up to 52 weeks after first adapting therapy, also for each adapting therapy
2) Factors related to achieving remission at 52 weeks after first adapting therapy, also for each adapting therapy
3) In the cases where MTX was started or increased as the initial treatment after registration, the relationship between the changes in disease activity by MTX treatment and that of the disease activity up to the 24 week and the 52 week after first adapting therapy, also for each adapting therapy
4) In case of starting or increasing MTX as the initial treatment after enrollment, analyze also for each factor relating to remission achievement at 24 and 52 weeks after first adapting therapy, also for each adapting therapy
5) Comparison of the changes in disease activity during adapting therapy between the groups which could and could not start treatment with MT
6) Trends of the following factors and relationship among factors in postmenopausal women: disease activity, biomarkers at the start of treatment (anti-CCP antibody, inflammatory cytokine, bone metabolism marker, cartilage metabolism marker), total Sharp score (Limb bone joint destruction), narrowing of knee joint joint space, DEXA
7) Content and outcome of serious adverse events occurring during observation

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) 1987 Classification criteria of American College of Rheumatology or 2010 American Rheumatology Association / European Rheumatology Association (ACR / EULAR) classification criteria are met.
2) Patients diagnosed within 6 months of RA who are not undergoing DMARD treatment or within 3 months
3) Patients who are over 20 years of age at the time of consent acquisition
4) Patients who received written explanations about the purpose and contents of this study, and obtained consent form freely by the person himself / herself in writing
Key exclusion criteria 1) Patients who have been treated with MTX exceeding 6 mg or who have been treated
2) Patients who are being treated with biologic drugs or targeted synthetic antirheumatic drugs or who have been treated
3) Patients who can not comply with dosage regimen
4) Patients who are deemed inappropriate for research by the research staff
Target sample size 685

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Toshihisa Kojima
Organization Nagoya University Hospital
Division name Orthopedic Surgery
Zip code
Address 65 Tsurumai-cho, Showa-ku, Nagoya
TEL 052-744-1908
Email toshik@med.nagoya-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Shuji Asai
Organization Nagoya University Hospital
Division name Center for Advanced Medicine and Clinical Research
Zip code
Address 65 Tsurumai-cho, Showa-ku, Nagoya
TEL 052-744-1908
Homepage URL
Email asai@med.nagoya-u.ac.jp

Sponsor
Institute Nagoya University Hospital
Orthopedic Surgery
Institute
Department

Funding Source
Organization Eli Lilly and Company
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 04 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2018 Year 05 Month 01 Day
Date of IRB
Anticipated trial start date
2018 Year 05 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information <Observation items and schedule>
1) Initial patient background: age sex duration of disease Complications
2) Baseline disease activity (swelling, number of tender joints / 28, patient and doctor general assessment VAS, CRP, MMP-3, HAQ-DI)
3) Collect disease-active HAQ-DI every 3 months after treatment start with anti-rheumatic drug. When treatment is strengthened, at the time of strengthening its treatment, disease activity after 1 month, 3 months later, every 3 months thereafter
4) Drug usage (DMARD, steroid) at the time of collection of disease activity data
Anti-CCP antibody inflammatory cytokine (TNF, IL-6) bone metabolism marker (PINP TRACP-5b Sclerostin RANKL) cartilage metabolism marker (TNF, IL-6 bone metabolism marker) three times after the beginning of therapy, (C2K, C2C).
6) Bone mineral density (lumbar femoral bone) At the start of DEXA, 1 year, 2 years
7) At the start of limbs and limbs, one year after two years
8) At the start of knee roentgen, two years after one year
9) Collect on adverse events that ceased or changed therapy.
10) Joint destruction evaluation by hand / foot X-ray: Performed with standard modified total sharp score
11) Knee X-ray evaluation: Measure the joint cleft by image analysis by computer assistance.

Management information
Registered date
2018 Year 03 Month 28 Day
Last modified on
2019 Year 02 Month 20 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035259

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.